Dobmeier Eric
SEC-identified person · CIK 1202785 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Structure Therapeutics Inc. GPCR | Director | filed 2023 - 2026 |
| Janux Therapeutics, Inc. JANX | Director | filed 2024 - 2026 |
| Jade Biosciences, Inc. JBIO | Director | filed 2025 - 2026 |
| Atara Biotherapeutics, Inc. ATRA | Director | filed 2015 - 2023 |
| Chinook Therapeutics, INC. KDNY | Director · President, CEO | filed 2020 - 2023 |
| Adaptive Biotechnologies Corp ADPT | Director | filed 2019 - 2021 |
| Versartis, Inc. VSAR | Director | filed 2017 - 2017 |
| Seagen Inc. SGEN | Sr. VP, Corporate Development | filed 2006 - 2017 |
| Stemline Therapeutics INC STML | Director | filed 2013 - 2017 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.